Search

Displaying results 2631 - 2640 of 3917 in total
  1. Drug

    Iodine

    go.drugbank.com/drugs/DB05382
    ApprovedInvestigational

    Iodine is commonly used as an antiseptic for minor cuts and abrasions, preventing infections that may result from contaminated wounds. Additionally, iodine has been studied in the treatment of fibrocystic disease and breast cancer.

    Mixtures: BION 3 FILM COATED TABLET, IODIO MARCO VITIProducts: IODIO MARCO VITI
  2. Drug

    Acacia

    go.drugbank.com/drugs/DB10451
    Approved

    Acacia allergenic extract is used in allergenic testing.

    Categories: Non-Standardized Plant Allergenic Extract
  3. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids.

  4. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...

  5. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes

    Synonyms: Mitoquinone ion
  6. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  7. Drug

    Radium Ra-223

    go.drugbank.com/drugs/DB12813
    Investigational

    Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).

  8. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394]

  9. Drug

    Tiragolumab

    go.drugbank.com/drugs/DB16409
    Investigational

    Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small

  10. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.